Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Abeona Therapeutics Inc. (NASDAQ: ABEO).

Full DD Report for ABEO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ABEO)

Abeona in-licenses REGENXBIO's NAV AAV9 vector for up to $580M
Abeona Therapeutics ( ABEO +1.2% ) inks an agreement with REGENXBIO ( RGNX -5.6% ) for exclusive global rights to its NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known a...
Source: SeekingAlpha
Date: November, 05 2018 11:23
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
ROCKVILLE, Md. , Nov. 5, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ®  Technology Platform, and Abeona Therapeut...
Source: PR Newswire
Date: November, 05 2018 07:00
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10 million paid upon signing, $10 million by first anniversary of agreement; annual paymen...
Source: GlobeNewswire
Date: November, 05 2018 07:00
Abeona Therapeutics: A Potential Leader In Gene Therapy
Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in...
Source: SeekingAlpha
Date: November, 01 2018 11:11
Abeona Therapeutics announces two new appointments
Abeona Therapeutics (NASDAQ: ABEO ) appoints of João Siffert, M.D. as Head of Research and Development and Chief Medical Officer (CMO). As a result, former CMO Juan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. More news on: Abeona Therapeutics Inc...
Source: SeekingAlpha
Date: October, 18 2018 09:18
Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer
NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of João Sif...
Source: Thomson Reuters ONE
Date: October, 18 2018 08:03
Investor Expectations to Drive Momentum within Cincinnati Bell, Hooker Furniture, AgroFresh Solutions, Forward Industries, Abeona Therapeutics, and Sientra - Discovering Underlying Factors of Influence
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cincinnati Bell Inc (NYSE:CBB), Hooker Furniture Corporation (NASDAQ:HOFT...
Source: GlobeNewswire
Date: October, 16 2018 07:55
Sarepta in-licenses gene therapy for Sanfilippo A from Lysogene
Sarepta Therapeutics (NASDAQ: SRPT ) inks an agreement with French biotech Lysogene for exclusive ex-Europe rights to gene therapy LYS-SAF302 for the potential treatment of mucopolysaccharidosis type IIIA ( MPS IIIA ), also known as Sanfilippo syndrome type A, a rare progressive disorder a...
Source: SeekingAlpha
Date: October, 15 2018 08:31
Premarket analyst action - healthcare
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: October, 12 2018 08:05
Abeona Announces Participation at Upcoming Conferences
NEW YORK and CLEVELAND, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that management will partici...
Source: GlobeNewswire
Date: September, 28 2018 08:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0813.6513.6514.2013.35466,164
2018-05-1721.0021.4521.4520.00883,056
2017-06-204.754.904.954.75127,532
2017-06-194.704.804.954.70138,505
2017-06-164.704.704.854.55191,091

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1241,247150,91727.3309Cover
2018-12-1189,222164,46554.2498Short
2018-12-10183,211344,02453.2553Short
2018-12-0782,927221,39137.4573Short
2018-12-0664,823151,73042.7226Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABEO.


About Abeona Therapeutics Inc. (NASDAQ: ABEO)

Logo for Abeona Therapeutics Inc. (NASDAQ: ABEO)

Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase development, and five preclinical development programs. The company s approved product is MuGard TM for the management of oral mucositis a common and debilitating side effect of many cancer therapies for which marketing authorization has been allowed by the FDA. Access ProLindac TM , a polymer linked platinum cancer drug is in Phase clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company s preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian Prodrax, a non toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company s Cobalamin TM oral drug delivery technology.

 

 

 

Current Management

  • David P. Nowotnik / SVP, R amp D
  • Phillip Wise / VP, Bus. Dev. NonProfit , VP, Strategy
  • Stephen B. Thompson / Vice President, CFO
  • Christine Berni / IR
  • Jeffrey B. Davis / Director
    • Mr. Davis has served as one of our directors since March . Since December , Mr. Davis has been President and Chief Executive Officer of Access Pharmaceuticals, Inc. Since April , Mr. Davis has been President of SCO Financial Group LLC and financial principal of SCO Securities LLC, a NASDregistered broker dealer. Prior to cofounding SCO, Mr. Davis served as Senior Vice President and Chief Financial Officer of HemaSure, Inc., a publicly traded development stage healthcare technology company. Prior to that, Mr. Davis was Vice President, Corporate Finance, at Deutsche Bank AG and Deutsche Morgan Grenfell, both in the U.S. and Europe. Mr. Davis also served in senior marketing and product management positions at AT amp T Bell Laboratories, where he was also a member of the technical staff. Prior to that, Mr. Davis was involved in marketing and product management at Philips Medical Systems North America. Mr. Davis served previously as a Director of Bioenvision, Inc. and currently serves as a Director of Access Pharmaceuticals, Inc., a publicly traded company. Mr. Davis holds a B.S. in Biomedical Engineering from the College of Engineering, Boston University and an M.B.A. from the Wharton School of Business, University of Pennsylvania.

Current Share Structure

  • Market Cap: $928,009,371 - 05/11/2018
  • Issue and Outstanding: 47,226,940 - 03/15/2018

 


Recent Filings from (NASDAQ: ABEO)

Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: May, 14 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Withdrawal of registration statement filed under the Securities Act
Filing Type: RWFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: ABEO)

Daily Technical Chart for (NASDAQ: ABEO)


Stay tuned for daily updates and more on (NASDAQ: ABEO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ABEO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABEO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ABEO and does not buy, sell, or trade any shares of ABEO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/